Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Jennifer Caudle, DO
Hope S. Rugo, MD, FASCO
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Charles Turck, PharmD, BCPS, BCCCP
Virginia Kaklamani, MD
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Samuel Yamshon, MD
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Ryan Quigley
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Jacob Sands, MD
Sandip Patel, MD
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Joshua K. Sabari, MD
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
Millie Das, MD
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Patrick McGill, MD
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Evandro Bezerra, MD
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Marwan G. Fakih, MD
Assessing Nivolumab + Ipilimumab in mNSCLC: 6-Year Outcomes from CheckMate 9LA
Martin Dietrich, MD, PhD
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
Aasma Shaukat, MD, MPH
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.